Lomustine and Bevacizumab in Progressive GlioblastomaWolfgang Wick, Martin J. van den Bent, Thierry Gorlia et al.|New England Journal of Medicine|2017Cited by 994
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J. van den Bent, Johan M. Kros, Paul M. Clément et al.|The Lancet|2017Cited by 401
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J. van den Bent, Brigitta G. Baumert, C. Mircea S. Tesileanu et al.|The Lancet Oncology|2021Cited by 333
LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIALWolfgang Wick, Martin J. van den Bent, Aa Brandes et al.|Neuro-Oncology|2015Cited by 79
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON TrialC. Mircea S. Tesileanu, Martin J. van den Bent, Marc Sanson et al.|Clinical Cancer Research|2022Cited by 74